Opinion: The U.S. Pharmaceutical Supply Chain Problem Is Not About China

A critical analysis challenges the prevailing narrative that frames pharmaceutical supply chain vulnerabilities primarily as a national security issue tied to China. According to healthcare policy expert Pooja Yerramilli, this geopolitical framing diverts attention from the actual structural weaknesses in the U.S. drug supply system. The real vulnerabilities stem from domestic manufacturing consolidation, inadequate inventory management, regulatory gaps, and economic pressures on producers rather than foreign dependency. Understanding these systemic issues is crucial for patients who depend on reliable medication access and for policymakers seeking to develop effective solutions that address root causes rather than geopolitical concerns.